Cambridge data firm Qureight raises £1.5m seed funding to accelerate clinical trials


Cambridge data company Qureight has raised £1.5m in seed funding to develop what is described as the world’s only AI-powered platform dedicated to complex diseases.

The technology has the potential to drastically reduce the costs of bringing life-saving drugs to market and shorten clinical trials.

Qureight – a play on the vicarious word – is led by CEO Dr Muhunthan Thillai, who is also a lung specialist at the Royal Papworth Hospital in Cambridge, while its scientific director is Dr Alessandro Ruggiero, who is also a radiology consultant in the city.

Qureight CEO Dr Muhunthan Thillai, left, and CSO Dr Alessandro Ruggiero

Its vision is to house the world’s largest collection of data on complex diseases.

Using proprietary technology, its platform allows scientists to track disease progression and drug response in patients with complex diseases. This helps develop unique biomarkers for use in clinical trials.

With each complex disease Phase III pharmaceutical study costing over £200m, the technology’s potential to improve the efficiency of clinical trials has proven attractive to investors, with Playfair Capital leading the way. of the tour and participation from life science funds Meltwind, Ascension and Cambridge Angels.

The company’s seed funding also comes the week it is named to the #21toWatch award shortlist, as we report this week.

One of Qureight’s early targets is idiopathic pulmonary fibrosis (IPF), a condition in which the lungs scar and breathing becomes increasingly difficult.

The company says last year it was the first in Europe to integrate complex datasets and software algorithms exploring lung scarring in patients with Covid-19.

Pioneering work has shown that changes in blood distribution in the lungs during Covid infection may partly explain why patients have such low blood oxygen levels. The finding could help lead to new methods of treating Covid patients by targeting the blood supply to the lungs.

Dr. Thillai demonstrated at the recent European Respiratory Society International Congress in Madrid that automated image analysis from lung CT scans, along with clinical data, can be used to track the progress of patients with scarring. lungs as the condition worsens and the disease progresses. .

“Existing treatments for pulmonary fibrosis are expensive, and clinical trials to find new drugs are often very large – requiring many patients to search for an outcome,” he said.

“Qureight’s technology platform will enable biopharmaceutical companies to recruit fewer patients for clinical trials and more accurately target the right type of patients – saving money and producing better results through a personalized approach to clinical trials. drug development.

The platform is designed to allow companies to manage, maintain and post-process clinical data in one place.

Users can upload imaging and biomarker data and transform clinical information into ready-to-use structured data. Proprietary tools are used for analysis and AI software solutions can be deployed for modeling.

Qureight, based at Nine Hills Road, already has other targets in sight.

Dr. Ruggiero explained: “Our next targets are pulmonary hypertension and adverse drug reactions in patients with complex lung cancer. This funding will allow us to use our platform to work with our biopharmaceutical partners to accelerate drug development in these areas.

Playfair Capital investor Jeevan Sunner said, “The cutting-edge clinical expertise of co-founders Dr. Thillai and Dr. Ruggiero has been crucial in Qureight’s development of the only global platform powered by AI dedicated to complex diseases.

“The technology offers an unparalleled integrated and secure solution for managing, analyzing and sharing clinical data – and is set to transform the way clinical trials are structured and, ultimately, patient treatment.”

Read more

AstraZeneca and BenevolentAI raise hopes for new IPF therapy


Comments are closed.